Ad
Tempus is a digital health company that uses artificial intelligence to provide personalized healthcare solutions. They have built the world's largest library of clinical and molecular data, starting with cancer. Main Features: AI Clinical Assistant: Tempus One, an AI-enabled clinical assistant, is available for all providers. It leverages advancements in generative AI to provide clinicians access to patient insights directly at their fingertips. Genomic Profiling: Tempus offers genomic profiling and algorithmic tests to help physicians make more informed treatment decisions. Clinical Trial Matching: The platform allows for fast, up-to-date clinical trials search using specific criteria. Digital Pathology: Tempus provides digital pathology services, including Tempus Pixel for therapy response evaluation and specific disease areas like lung, breast, neuro, and cardio. Sequencing and Data Collaborations: Tempus offers sequencing services and promotes data collaborations for better drug development. Clinical Research Services: Tempus provides services for clinical trial enrollment and has a platform called Tempus PRO™ for neurology and psychiatry. EHR Integration: Tempus supports EHR integration for seamless data access and management. Publications: Tempus regularly publishes research, webinars, and other resources to stay informed about the latest developments in personalized healthcare. Use Cases: Providers: Tempus helps physicians make more informed treatment decisions. Life Sciences: Tempus assists pharmaceutical and biotech companies with better drug development. Patients: Tempus helps patients find their own unique and optimal therapy options. Notable Achievements: Tempus’ xT Platform increases cancer patients’ personalized therapeutic opportunities. FDA granted Tempus Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test. Tempus launched a standalone RNA next-generation sequencing assay, Tempus xR. Tempus has partnerships with 90% of the top 20 pharma oncology companies and over 200 biopharma partnerships. More than 50% of all Academic Medical Centers and oncologists in the US are connected to Tempus. Tempus has over 6,000,000+ de-identified research records and has identified over 24,000+ patients for potential enrollment into clinical trials in their network.
